13 August 2018
Visiongain’ has launched a new pharma report Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs
Shifting diets and lifestyle choices are associated with increases in wealth and the level of development of a country’s economy. With the rapid growth seen in markets such as the BRIC markets, as well as other nations such as Mexico, rates of high cholesterol have been increasing in these nations. Many of the drugs currently used for the control of cholesterol levels have or are soon going to see their patents expire, allowing for generic competition. This has been particularly prevalent among statins, as many of these were developed some time ago.
There is a strong pipeline for cholesterol-lowering drugs; many of which will launch within the next two to three years. New drug classes such as PCSK9 inhibitors will open up new areas of treatment, as they allow further treatment of patients with very high cholesterol levels. The impact of new treatments will lead to a significant rise in global revenues in the market. The addition of further indications for these new products at a later date would allow for further expansion of their use.
The lead analyst of the report commented “Visiongain believes the major drivers of growth in the global cholesterol-lowering drugs market will be: increasing demand for cholesterol-lowering drugs due to population growth and the increasing prevalence of high cholesterol, improvements in the management and treatment of high cholesterol, increasing healthcare expenditure, especially in a number of emerging economies and he launch of new drugs such as PCSK9 inhibitors”
Leading companies featured in the report include AstraZeneca, Merck & Co, Pfizer, Kowa Company, Daiichi Sankyo, AbbVie, Novartis, Sanofi, Amgen, Bristol-Myers Squibb (BMS).
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.